Smith & Nephew Cut Its 2026 Sales Outlook. The Real Test Starts Now.

Smith & Nephew's 2026 growth outlook just got less forgiving

Smith & Nephew still delivered decent profit, but the growth outlook moved the wrong way at the worst time. Management now sees around 4% full-year revenue growth, down from 6%, after a second quarter that reached $1.597 billion and posted 1.6% underlying revenue growth. That forces investors to look past execution rhetoric and judge whether this is a temporary stumble or the start of a tougher year.

The bullish case is not baseless. Smith & Nephew produced $566 million of first-half trading profit at an 18.3% margin, and management said that was supported by $128 million in efficiency savings and tariff refunds. The operating machine is still working. The harder question is why better cost control is doing more of the heavy lifting while demand softens, especially with the company cutting its growth outlook midyear.

Sports Medicine is holding up; the core orthopaedics and wound areas are not

What is still working

Sports Medicine and ENT remain the clearest bright spot. That unit grew 8.6% on an underlying basis, helped by joint-repair products such as REGENETEN and Q-FIX KNOTLESS. Even from the first quarter, management said more than half of growth came from innovation launched in the last 5 years. That does not solve the whole problem, but it shows some parts of the portfolio still have real demand.

Where the bigger revenue engines are slipping

The problem is where the weakness sits. U.S. Orthopaedics and Advanced Wound Bioactives are the heavier, more consistent earners, and both are under pressure. Advanced Wound Bioactives declined 12.7%, while management specifically pointed to U.S. Knees and SANTYL when explaining the outlook cut.

That makes this more than a routine miss. Sports Medicine can support the narrative, but slower growth in knees and certain wound products matters more to earnings durability because they are steadier contributors to the overall base.

Cost discipline can buffer the half-year story, but it cannot replace demand

Management has lifted its efficiency savings target to $200 million for the full year, up from $150 million, and earlier guidance still pointed to around 8% trading profit growth. That provides some support, but it is still important not to confuse a leaner cost base with healthier demand.

Free cash flow is the cleaner reality check. Smith & Nephew generated $231 million in the first half, compared with $244 million a year earlier. That is not a break in cash generation, but it does show that softer revenue growth required more care around working capital and cash conversion.

What the next quarter needs to show

The near-term test is straightforward: investors need evidence that the weak areas are stabilizing, not just that savings are masking the slowdown. The constructive signal would be profit still trending toward around 8% trading profit growth, SANTYL returns to growth, and clearer recovery momentum in orthopaedics. If the savings program lifts profit while the core orthopaedics and wound softness persists, the market will likely keep questioning the quality of the recovery.